title: New treatment developments applied to elderly patients with advanced prostate cancer.
abstract: Prostate cancer is a common disease amongst elderly men. Compared with younger patients, men over the age of 75 are more likely to present with advanced disease and have a greater risk of death from prostate cancer despite higher death rates from competing causes. Treatment options for advanced prostate cancer have improved considerably in the last two years. The immunotherapy sipuleucel-T, the cytotoxic cabazitaxel, the androgen biosynthesis inhibitor abiraterone acetate, the radioisotope radium-223 and the antiandrogen enzalutamide have all been shown to improve survival in randomized phase III studies for patients with metastatic castration-resistant prostate cancer. This review will focus on the clinical data regarding new treatment developments specifically applied to elderly patients with advanced prostate cancer.
authors.affiliation: Department of Hematology/Oncology, American University of Beirut Medical Center, P.O. Box 11-0236, Riad El Solh, Beirut 1107 2020, Lebanon. Dm25@aub.edu.lb
authors.forename: Deborah
authors.initials: D
authors.lastname: Mukherji
authors.forename: Carmel J
authors.initials: CJ
authors.lastname: Pezaro
authors.forename: Ali
authors.initials: A
authors.lastname: Shamseddine
authors.forename: Johann S
authors.initials: JS
authors.lastname: De Bono
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery* / Q000628:therapy
chemical_list: D018931:Antineoplastic Agents, Hormonal